Jeetu Pathak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jeetu Pathak has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Divya Kanchibhotla
Sri Sri Institute For Advanced Research
2 shared publications - Hari Venkatesh
Sriveda Sattva Pvt. Ltd
2 shared publications - Ravi Reddy
Sriveda Sattva Pvt. Ltd
2 shared publications Monika Pathania
All India Institute for Medical Science, Rishikesh
1 shared publication
Latest Publications
- Open Access
- 5 October 2021
- Published by Springer Nature in Research Square
In vivo efficacy and safety of Siddha medicine Kabasura Kudineer among COVID 19 infected Syrian golden hamsters.
Background: The COVID-19 pandemic has overburdened current healthcare system and highlighted the need to explore potent remedies in Traditional medicine systems. Kabasura Kudineer (KSK), a poly herbal Siddha medicine, has shown great potential in treating COVID-19.Objective: The objective of the study is to explore the safety and efficacy of Kabasura Kudineer in a preclinical model for COVID-19: Syrian Golden Hamsters.Methods: This research study investigates the in vivo efficacy and safety of the well-known antiviral Siddha medicine KSK as a powdered tablet on COVID-19 infected Syrian golden hamsters. A total of 19 female hamsters were infected with the virus cell culture through intranasal route. 4 out of 19 animals were mock controls, 5 were infection controls, 4 were treated with remdesivir and acted as positive controls and remaining 6 were treated with KSK. The hamsters were observed for any adverse events, followed by their sacrifice on day 4 after inoculation with the virus. The lung pathology and viral load was studied for each hamster.Results: Therapeutic use of intraperitoneal instillation of Siddha formulation KSK reduces SARS-CoV-2 viral load and associated gross clinical parameters. Results showed significant reduction of 65% in the viral load for the KSK arm as compared to the infection control.Conclusion: We observed that the animals treated with KSK exhibited less severe pathology compared to the untreated infected group. No toxicity or adverse events were observed in the KSK group. This pre-clinical study supports the safety and efficacy of KSK.Study Registration: FNDR’s Institutional Animal Ethics Committee (IAEC), Registration Number 2082/PO/Rc/S/19/CPCSEA
- 5 October 2021
- Published by Springer Nature in Research Square
Open AccessIn vivo efficacy and safety of Siddha medicine Kabasura Kudineer among COVID 19 infected Syrian golden hamsters.
Background: The COVID-19 pandemic has overburdened current healthcare system and highlighted the need to explore potent remedies in Traditional medicine systems. Kabasura Kudineer (KSK), a poly herbal Siddha medicine, has shown great potential in treating COVID-19.Objective: The objective of the study is to explore the safety and efficacy of Kabasura Kudineer in a preclinical model for COVID-19: Syrian Golden Hamsters.Methods: This research study investigates the in vivo efficacy and safety of the well-known antiviral Siddha medicine KSK as a powdered tablet on COVID-19 infected Syrian golden hamsters. A total of 19 female hamsters were infected with the virus cell culture through intranasal route. 4 out of 19 animals were mock controls, 5 were infection controls, 4 were treated with remdesivir and acted as positive controls and remaining 6 were treated with KSK. The hamsters were observed for any adverse events, followed by their sacrifice on day 4 after inoculation with the virus. The lung pathology and viral load was studied for each hamster.Results: Therapeutic use of intraperitoneal instillation of Siddha formulation KSK reduces SARS-CoV-2 viral load and associated gross clinical parameters. Results showed significant reduction of 65% in the viral load for the KSK arm as compared to the infection control.Conclusion: We observed that the animals treated with KSK exhibited less severe pathology compared to the untreated infected group. No toxicity or adverse events were observed in the KSK group. This pre-clinical study supports the safety and efficacy of KSK.Study Registration: FNDR’s Institutional Animal Ethics Committee (IAEC), Registration Number 2082/PO/Rc/S/19/CPCSEA
- Open Access
- 28 September 2021
- Published by Springer Nature in Research Square
In vitro evaluation of antiviral efficacy of a Siddha Formulation against SARS-CoV-2
Introduction: SARS-CoV-2 virus caused COVID-19 pandemic with 218 million cases and 45 million deaths world over. It has challenged the already overburdened healthcare systems and created an urgent need to investigate solutions present in other healthcare systems. In this study Kabasura Kudineer is investigated as an intervention to influence the immune response which is beneficial for the host and stop the viral replication. Methods: Kabasura Kudineer is a polyherbal formulation containing 15 herbal drugs mixed in equal quantity. It is an official Siddha formulation, used for phlegmatic fevers and flu-like symptoms. To conduct this study Vero E6 (CL1008), the African monkey kidney epithelial cell line was taken and infected with SARS-CoV-2 viral isolate. The Kabasura Kudineer was added in different concentrations; 0.5 mg/mL, 0.25 mg/mL, 0.12 mg/mL, 0.06 mg/mL and 0.03 mg/mL to the infected cells respectively. These cell plates were incubated for 3 days in 5% CO2 incubator. Remdesivir was used as a positive control. The cells were fixed with formaldehyde, stained with crystal violet and plaques were visualised. Plaques were counted as PFU/ml. Result: Kabasura Kudineer was found to exhibit good antiviral activity against SARS-CoV-2. The highest antiviral activity was 81.5% at a concentration of 0.5 mg/ml. The IC-50 value was found to be 0.2 mg/mL. Conclusion: The antiviral efficacy of Kabasura Kudineer in our study showed reduction in the viral load which supports the results of clinical studies. Kabasura Kudineer can be used widely in a clinical setting as a treatment for COVID-19.
- 28 September 2021
- Published by Springer Nature in Research Square
Open AccessIn vitro evaluation of antiviral efficacy of a Siddha Formulation against SARS-CoV-2
Introduction: SARS-CoV-2 virus caused COVID-19 pandemic with 218 million cases and 45 million deaths world over. It has challenged the already overburdened healthcare systems and created an urgent need to investigate solutions present in other healthcare systems. In this study Kabasura Kudineer is investigated as an intervention to influence the immune response which is beneficial for the host and stop the viral replication. Methods: Kabasura Kudineer is a polyherbal formulation containing 15 herbal drugs mixed in equal quantity. It is an official Siddha formulation, used for phlegmatic fevers and flu-like symptoms. To conduct this study Vero E6 (CL1008), the African monkey kidney epithelial cell line was taken and infected with SARS-CoV-2 viral isolate. The Kabasura Kudineer was added in different concentrations; 0.5 mg/mL, 0.25 mg/mL, 0.12 mg/mL, 0.06 mg/mL and 0.03 mg/mL to the infected cells respectively. These cell plates were incubated for 3 days in 5% CO2 incubator. Remdesivir was used as a positive control. The cells were fixed with formaldehyde, stained with crystal violet and plaques were visualised. Plaques were counted as PFU/ml. Result: Kabasura Kudineer was found to exhibit good antiviral activity against SARS-CoV-2. The highest antiviral activity was 81.5% at a concentration of 0.5 mg/ml. The IC-50 value was found to be 0.2 mg/mL. Conclusion: The antiviral efficacy of Kabasura Kudineer in our study showed reduction in the viral load which supports the results of clinical studies. Kabasura Kudineer can be used widely in a clinical setting as a treatment for COVID-19.